Teladoc expands its weight care program to give employers a new way to cover...
The virtual care company is betting that predictable medication spending and clinical support can make GLP-1 coverage workable for more employers
Isomorphic Labs raises $5bn, and it still hasn’t dosed a patient
The DeepMind spinout's Series C comes six months after a $2.1bn round, a bet that AI-designed drugs will reach the clinic
Remedy Robotics raises $62M to take remote stroke thrombectomy toward FDA review
The Series B funds a pivotal neurovascular trial for the N1 System, a catheter robot built to put specialist skill where specialists are not
ChatGPT for Healthcare adds agents that click through your EHR
OpenAI is pairing computer-use agents, better cited clinical answers, and more than 20 new plugins to tackle the busywork between healthcare systems
WHOOP wants to be the social network that bots can’t join
The wearable maker's new WHOOP Humans feature lets members follow friends and share health data, with a verified heartbeat behind every account
Huawei enters the CGM market with the Sense G1, and it comes with a...
The company's first continuous glucose monitor is a 16-day, calibration-free arm sensor. Price and release date are still unknown.
Apple wants to know if you trust health AI, and it’s asking 200,000 people
The Apple Health AI Usage Study, built with OpenEvidence, will examine how people understand and act on conversational health answers
GoodRx plugs drug pricing into Google’s Gemini for healthcare
A new MCP integration puts prescription costs and manufacturer self-pay programs inside the AI tools care teams already use
Google puts a governed AI agent between clinicians and their fragmented data
Gemini for healthcare, now in preview, aims to assemble records, check payer policy and prepare authorizations without anyone switching systems
A first-time VC bets that AI will eat pharma’s outsourced work
Sahir Raoof raised $27.5 million for Proximal Ventures in a brutal market for emerging managers, wagering that AI can take over the services drugmakers have long bought from contractors









